1 active not recruiting, 1 terminated. 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Floor Backes, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Lenvatinib, Paclitaxel, Pembrolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Floor Backes, MD | 38 | 2021-09-01 | 2026-10-21 |
| Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer Biopsy, Carboplatin, Paclitaxel - Lynch Syndrome, Recurrent Endometrial Carcinoma | Early Phase 1 | Terminated | Floor Backes, MD | 2 | 2021-07-01 | 2025-02-13 |
Endometrial Neoplasms (2) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1) · Turcot syndrome (1)
Paclitaxel (2) · Taxes (2) · Biopsy (1) · Carboplatin (1) · lenvatinib (1) · pembrolizumab (1) · tislelizumab (1)
United States (2)